ARTICLE
24 February 2014

A Guide To The FDA’s Proposed Social Media Guidance

M
Mintz

Contributor

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.
The FDA recently proposed guidance for the submission of materials disseminated through real-time social media promotions for postmarketing reporting purposes.
United States Media, Telecoms, IT, Entertainment

The FDA recently proposed guidance for the submission of materials disseminated through real-time social media promotions ("Interactive Promotional Media") for postmarketing reporting purposes.

Under existing FDA postmarketing reporting requirements, manufacturers, packers, and distributors that are FDA applicants or that act on behalf of FDA applicants ("Applicants") are required to submit all promotional labeling and advertising pieces at the time of an advertisement's initial publication.  The draft guidance provides nonbinding recommendations on how Applicants can satisfy the postmarketing reporting requirements while engaging customers through Interactive Promotional Media.

For a summary of the proposed guidance and a useful chart for Applicants, read the Mintz Levin alert authored by Cynthia J. Larose and Jonathan P. Ursprung.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More